Borst J, van Dongen J J, Bolhuis R L, Peters P J, Hafler D A, de Vries E, van de Griend R J
Department of Immunology, Netherlands Cancer Institute, Amsterdam.
J Exp Med. 1988 May 1;167(5):1625-44. doi: 10.1084/jem.167.5.1625.
A second type of TCR molecule has been identified on human and murine T lymphocytes, which involves the protein products of the gamma and delta genes. T lymphocytes bearing this receptor may constitute a separate cell lineage with a distinct immune function. We have produced an mAb, which specifically detects human TCR-gamma/delta in native as well as denatured states, this in contrast to previously used anti-gamma chain peptide sera, which only reacted with denatured protein. The receptor occurs in different molecular forms, with or without interchain disulphide bonds, in which a delta chain may or may not be detected by cell surface iodination. The mAb is reactive with all these receptor forms. Therefore, this antibody could be used to determine the expression of TCR-gamma/delta on viable human T lymphocytes. In normal individuals, TCR-gamma/delta was found on a subset composing 2-7% of CD3+ lymphocytes in peripheral blood and 0.1-1.0% in thymus. The majority of these cells do not express the CD4 or CD8 antigens, although a significant percentage of CD8+ cells was found. TCR-gamma/delta+ cells in peripheral blood are resting lymphocytes, as judged by ultrastructural analysis. T cell clones with different receptor types can display MHC-nonrestricted cytolytic activity, which is shown to be induced by the culture conditions, most likely by growth factors such as IL-2. This strongly suggests that TCR-gamma/delta does not play a role in target cell recognition in MHC-nonrestricted cytotoxicity. The anti-TCR-gamma/delta antibody can specifically induce cytotoxic activity in clones expressing the receptor, but in addition inhibit growth factor induced cytotoxicity, which indicates a regulatory role of the TCR-gamma/delta/CD3 complex in MHC-nonrestricted cytotoxicity.
在人和小鼠的T淋巴细胞上已鉴定出第二种类型的TCR分子,它涉及γ和δ基因的蛋白质产物。带有这种受体的T淋巴细胞可能构成具有独特免疫功能的独立细胞谱系。我们制备了一种单克隆抗体,它能特异性检测天然状态以及变性状态下的人TCR-γ/δ,这与之前使用的抗γ链肽血清不同,后者仅与变性蛋白发生反应。该受体以不同的分子形式存在,有或没有链间二硫键,其中通过细胞表面碘化可能检测到或检测不到δ链。这种单克隆抗体能与所有这些受体形式发生反应。因此,这种抗体可用于确定TCR-γ/δ在有活力的人T淋巴细胞上的表达。在正常个体中,在外周血中发现TCR-γ/δ存在于占CD3+淋巴细胞2%-7%的一个亚群中,在胸腺中占0.1%-1.0%。这些细胞中的大多数不表达CD4或CD8抗原,尽管发现有相当比例的CD8+细胞。通过超微结构分析判断,外周血中的TCR-γ/δ+细胞是静息淋巴细胞。具有不同受体类型的T细胞克隆可表现出MHC非限制性细胞溶解活性,已证明这种活性是由培养条件诱导的,最有可能是由诸如白细胞介素-2等生长因子诱导的。这强烈表明TCR-γ/δ在MHC非限制性细胞毒性中不参与靶细胞识别。抗TCR-γ/δ抗体能在表达该受体的克隆中特异性诱导细胞毒性活性,但此外还能抑制生长因子诱导的细胞毒性,这表明TCR-γ/δ/CD3复合物在MHC非限制性细胞毒性中具有调节作用。